Market Overview

UPDATE: Stifel Nicolaus Raises PT to $40 on Theravance on Improved Risk Profile

Related THRX
Short-Sellers Betting Against These Biotechs
Morning Market Losers

Stifel Nicolaus reiterated its Buy rating on Theravance (NASDAQ: THRX) and raised its price target from $28 to $40.

Stifel Nicolaus noted, "We believe recently-announced top-line P3 LAMA/LABA data implies a relatively clear regulatory path forward and our physician conversations suggest the utilization of these combined mechanisms of action should gain considerable traction/adoption in those moderate/severe COPD patients whom require prolonged/significant bronchodilation."

Therevance closed at $29.49 on Friday.

Latest Ratings for THRX

May 2015Cowen & CompanyDowngradesMarket Perform
Jul 2014Bank of AmericaDowngradesBuyNeutral
Jun 2014Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for THRX
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (THRX)

Get Benzinga's Newsletters